Voyager Therapeutics, Inc.
VYGR
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington'sā¦ read more
Healthcare
Biotechnology
9 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$4.23
Price+0.24%
$0.01
1Y
Price
Market Cap
$234.633m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-683.8%
EBITDA Margin-642.0%
Net Profit Margin-660.9%
Free Cash Flow MarginRevenue
$42.580m
-46.8%
1y CAGR+132.1%
3y CAGR+101.4%
5y CAGREarnings
-$107.934m
-66.0%
1y CAGR+56.7%
3y CAGR+49.9%
5y CAGREPS
-$1.85
-63.7%
1y CAGR+47.9%
3y CAGR+43.6%
5y CAGRBook Value
$243.944m
$322.101m
Assets$78.157m
Liabilities$40.204m
DebtDebt to Assets
12.5%
-0.3x
Debt to EBITDAFree Cash Flow
-$115.829m
-515.1%
1y CAGR-14.2%
3y CAGR+7.6%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company